Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. reported that its Chief Medical Officer, Dongfang Liu, received a grant of stock options covering 748,130 shares of common stock. The award is classified as a grant or other acquisition rather than an open-market purchase.
According to the terms, the option vests as to 25% of the underlying shares on the one-year anniversary of February 27, 2026, with the remaining portion vesting in equal monthly installments over the following 36 months. Vesting is conditioned on Dr. Liu’s continuous service with the company on each applicable vesting date.
Nuvation Bio Inc. reported that officer Makunje Moses received new equity awards. On February 27, 2026, Moses was granted stock options for 224,439 shares at an exercise price of $0.00 per share and 50,761 shares of Class A Common Stock as restricted stock units (RSUs).
The stock option vests 25% on the one-year anniversary of February 27, 2026, then monthly over the next 36 months, contingent on continued service. The RSUs vest in four equal annual installments on the issuer’s quarterly vesting date following each of the first four anniversaries from February 27, 2026, also conditioned on continued service.
Nuvation Bio Inc. reported that Chief Regulatory Officer Kerry Wentworth received a grant of stock options covering 748,130 shares of common stock on February 27, 2026. The option has an exercise price of $0.00 per share and vests 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to continued service. Following this grant, Wentworth also holds 53,000 shares of Class A common stock, including 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc.'s Chief Commercial Officer, Colleen Sjogren, received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest as to 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to her continuous service. Following this grant, she directly owned 84,000 shares of Class A common stock, which includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc. reported that Chief Financial Officer Philippe Sauvage received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to his continuous service.
Following this grant, Sauvage directly holds 12,673 shares of Class A common stock. This total includes 2,771 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc. reported that its Chief People Officer, Markel Stacy, was granted a stock option covering 748,130 shares of Class A common stock on February 27, 2026. The option vests 25% on the one-year anniversary of February 27, 2026 and then monthly over the following 36 months, contingent on her continued service.
After this grant, Stacy holds 748,130 stock options and 32,591 shares of Class A common stock directly, including 3,000 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.
Cui Xiangmin reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that director Xiangmin Cui received a grant of stock options covering 74,813 shares on February 27, 2026. The options have a grant price of $0.00 per share and represent a right to buy company stock rather than immediate ownership.
According to the terms, the option vests as to 1/24 of the shares on the one-month anniversary of January 1, 2026, and then monthly over the following 23 months, as long as Cui remains in continuous service on each vesting date. After this grant, Cui holds 74,813 stock options directly.
Hattersley Gary reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that its Chief Scientific Officer, Gary Hattersley, received a grant of stock options covering 748,130 shares of common stock. The options were awarded at a grant price of $0.00 per option, reflecting a non-cash compensation award rather than an open-market purchase.
According to the vesting terms, 25% of the option grant will vest on the one-year anniversary of 2/27/2026, with the remaining portion vesting in equal monthly installments over the following 36 months, subject to his continuous service on each vesting date.
Nuvation Bio Inc. reported that its Chief Technical Operations officer, David C. Hanley, received a grant of 748,130 stock options. These options were acquired as a derivative security award and increase his directly held option position to 748,130 options.
According to the terms, the option vests as to 25% on the one-year anniversary of February 27, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on Hanley’s continuous service on each vesting date.
Hung David reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that President and CEO David Hung received a grant of stock options covering 1,995,012 shares. These options were awarded at no cash cost to him as a grant, not an open-market purchase.
According to the disclosure, the option vests 25% on the one-year anniversary of 2/27/2026, with the remaining shares vesting monthly over the following 36 months, as long as he continues in service on each vesting date.